Bibliography
- Orphan Drug Regulations (57 FR 62076), December 29, 1992 and 21 CFR Part 316 et seq
- Blankart CR, Stargardt T, Schreyogg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, fabry disease, hereditary angioedema and chronic myeloid leukemia. Pharmacoeconomics 2011;29:63-82
- Kaitin KI. editor. U.S. Orphan product designations more than doubled from 2000-02 to 2006-08: Tufts Center for the Study of Drug Development impact report. Volume 12(1) Tufts Center for the Study of Drug Development; Boston, Massachusetts: 2010
- European Parliament. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Official J Eur Communities 2000;22(1):L 18/1
- McCaughan M. Big pharma and orphan drugs: the case for thinking small. RPM Rep 2009;4:10-11
- Bennett S. Orphan drug prices under siege in austerity-minded Europe. Bloomberg News. 2013. Available from: http://www.bloomberg.com/news/2013-04-07/orphan-drug-prices-under-siege-in-austerity-minded-europe.html
- Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis 2008;3:33
- Rosenberg-Yunger Z, Daar A, Thorsteinsdottir H, Martin D. Priority setting for orphan drugs: an international comparison. Health Policy 2011;10:25-34
- Largent E, Pearson S. Which orphans will find a home: the rule of rescue in resource allocation for rare diseases. Hastings Cent Rep 2012;42:27-34
- Klepser D, Huether J, Handke L, Williams C. Effect on drug utilization and expenditures of a cost-share change from co-payment to co-insurance. J Manag Care Pharm 2007;13:765-77
- Cohen JP, Malins A, Shahpurwala Z. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs. Health Aff 2013;32:762-70
- Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 2012;7:74
- Dupont A, van Wilder P. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol 2011;71(4):488-96
- Herper M. Inside the pricing of a $300,000-a-year drug. Forbes Magazine. 2013. Available from: http://www.forbes.com/sites/matthewherper/2013/01/03/inside-the-pricing-of-a-300000-a-year-drug/
- Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis 2011;6:62
- Simoens S. Pricing and reimbursement of orphan drugs: the need for transparency. Orphanet J Rare Dis 2011;6:42
- Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefits 2010;3(1):15-23
- Tilles SA, Borish L, Cohen JP. Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectives. Ann Allergy Asthma Immunol 2013;110(2):70-4